Want to see VCNX full AI Analyst Report?
VCNX Stock Chart & Stats
$1.18
$0.00(0.00%)
At close: 4:00 PM EDT
$1.18
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.31 - $1.50
Previous CloseN/A
Volume2.00
Average Volume (3M)1.22K
Market Cap
$2.65M
Enterprise Value$1.65M
Total Cash (Recent Filing)$1.11M
Total Debt (Recent Filing)$25.00K
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.48
Shares Outstanding2,676,637
10 Day Avg. Volume776
30 Day Avg. Volume1,224
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.38
Price to Sales (P/S)1.38
P/FCF Ratio-0.45
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue2.74
Enterprise Value/Gross Profit2.87
Enterprise Value/Ebitda-0.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Acceleration2025 revenue growth of ~249% to ~$2.10M demonstrates accelerating top-line traction for a clinical-stage biotechs' programs. Sustained revenue expansion can fund clinical R&D, improve bargaining position for partners, and enable operating leverage if growth persists.
High Gross MarginVery high gross margins indicate low direct costs on reported revenue, so incremental sales can contribute strongly to gross profit. If clinical successes translate into recurring revenue, this margin profile supports longer-term profitability and scalable returns on R&D investment.
Improving Cash BurnOperating cash flow improved materially year-over-year, suggesting tighter expense control or lower financing needs. A reduced burn rate extends runway, lowers near-term dilution risk, and provides more time to advance clinical programs or secure strategic partnerships.
Bears Say
Negative EquityNegative shareholders' equity (~ -$7.59M) signals a capital deficit and weak balance-sheet buffer. This reduces financial flexibility, increases reliance on external financing, and elevates solvency and restructuring risk if operating losses continue.
Persistent Net LossesRecurring multi-year net losses constrain the firm's ability to self-finance development and heighten the need for capital raises or partner deals. Chronic unprofitability undermines long-term sustainability absent sustained revenue growth or meaningful cost restructuring.
High Leverage Vs Asset BaseA small asset base relative to rising debt (~$1.80M assets vs ~$5.52M debt) creates elevated refinancing and solvency risk. High leverage limits strategic options, may raise borrowing costs, and could force dilutive financing or asset sales to fund operations.
Vaccinex News
VCNX FAQ
What was Vaccinex Inc’s price range in the past 12 months?
Vaccinex Inc lowest stock price was $0.31 and its highest was $1.50 in the past 12 months.
What is Vaccinex Inc’s market cap?
Vaccinex Inc’s market cap is $2.65M.
When is Vaccinex Inc’s upcoming earnings report date?
Vaccinex Inc’s upcoming earnings report date is Nov 16, 2026 which is in 97 days.
How were Vaccinex Inc’s earnings last quarter?
Currently, no data Available
Is Vaccinex Inc overvalued?
According to Wall Street analysts Vaccinex Inc’s price is currently Overvalued.
Does Vaccinex Inc pay dividends?
Vaccinex Inc does not currently pay dividends.
What is Vaccinex Inc’s EPS estimate?
Vaccinex Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaccinex Inc have?
Vaccinex Inc has 2,676,637 shares outstanding.
What happened to Vaccinex Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vaccinex Inc?
Currently, no hedge funds are holding shares in VCNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vaccinex Inc
Vaccinex, Inc. is a biotechnology firm operating in the clinical stage, dedicated to identifying and developing specialized biological therapies. Its core mission is to address serious medical conditions and diseases that currently lack adequate treatment options. The company's therapeutic endeavors encompass a broad spectrum of illnesses, including various forms of cancer, neurodegenerative disorders, and autoimmune diseases. At the forefront of its pipeline is pepinemab, a humanized monoclonal antibody. This leading candidate has either concluded or is scheduled for Phase 1b/2 clinical investigations, exploring its efficacy against non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. Furthermore, Vaccinex is progressing with VX5, a human antibody targeting CXCL13, which is presently in preclinical assessment for potential application in multiple sclerosis (MS) and other autoimmune conditions. The company was established in 2001 and has its principal operations located in Rochester, New York.
Technical Analysis
Theriva Biologics
―
GT Biopharma
―
Revelation Biosciences
―
CERo Therapeutics Holdings
―
Azitra Inc
―
Ownership Overview
―
Insiders
―
Mutual Funds
6.13% Other Institutional Investors
93.87% Public Companies and
Individual Investors